Full Text (PDF)
Review Article

Pharmacological Management of Coronavirus Disease 2019

Divya Krupa Muniyandi , Divya Krupa Muniyandi

Author Information

Licence:




Indian Journal of Communicable Diseases 7(1):p 27-30, January-June 2021. | DOI: http://dx.doi.org/10.21088/ijcd.2395.6631.7121.4

How Cite This Article:

Divya Krupa Muniyandi, Pharmacological Management of Coronavirus Disease 2019. Indian J Comm Dis.2021;7(1):27–30.


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

The incidence and vast spread of the coronavirus disease 2019 has been quite rapid across the globe. There is no medicine approved solely by the FDA for the management of COVID-19 infection. Only symptomatic management is carried out in patients with the available medicines in the market. This review provides an overview of the drugs which are being used primarily for the management of the infection across the globe. The number of drugs being used is comparatively less, hence to provide a view on the mechanism and pharmacology, this review has been carried out. Data on drugs like remdesivir, dexamethasone and tocilizumab have been included in this review, along with supportive care from Siddha to help the medical fraternity to decide on the treatment regimen for COVID-19. Data on the current use of drugs in hospitals were provided by a medical practitioner and are included in this review.

Keywords: COVID-19; Management; Remdesivir; Dexamethasone; Tocilizumab.


References

No records found.


About this article


Cite this article

Divya Krupa Muniyandi, Pharmacological Management of Coronavirus Disease 2019. Indian J Comm Dis.2021;7(1):27–30.


Licence:




Received Accepted Published
N/A N/A N/A

DOI: http://dx.doi.org/10.21088/ijcd.2395.6631.7121.4

Keywords


Article Level Metrics

Last Updated

Wednesday 17 June 2026, 16:07:28 (IST)


557

Accesses

3
217
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share